The potential for immunoconjugates in lymphoma therapy.

Publication Type:

Journal Article


Hematology/oncology clinics of North America, Volume 11, Issue 5, p.987-1006 (1997)


Animals, Antibodies, Monoclonal, Antibody Specificity, Antigens, Neoplasm, Clinical Trials as Topic, Disease-Free Survival, Humans, Immunocompetence, Immunoconjugates, Immunotoxins, Lymphoma, Non-Hodgkin, MICE, Recombinant Fusion Proteins, Treatment Outcome


Contemporary combination chemotherapy offers curative treatment for 30% to 50% of patients with advanced-stage, aggressive non-Hodgkin's lymphomas (NHL). However, conventional therapies cure few patients with indolent lymphomas or relapsed lymphomas of any histology. Myeloablative chemoradiotherapy with bone marrow or stem cell transplantation can provide pro-longed disease-free survival for a minority (20% to 50%) of patients with relapsed NHL, but new treatment approaches are clearly needed. In recent years, several groups of investigators have provided preliminary evidence suggesting that monoclonal antibodies (mAbs), in unmodified form or conjugated to toxins, drugs, or radioisotopes, may offer another effective therapeutic modality for patients with relapsed lymphomas. This article reviews current immunotherapy of NHL using antibody immunoconjugates.